Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin’s lymphoma

Abstract

Purpose

Vascular endothelial growth factor (VEGF) plays an important role in tumor angiogenesis and cancer progression. The VEGF genetic polymorphisms were shown to be independently associated with an adverse outcome in various malignancies. We investigated the possible associations of two polymorphisms (−2578C/A and +936C/T) in the VEGF gene with the clinicopathologic parameters for patients with non-Hodgkin’s lymphoma (NHL).

Methods

We studied the genotype and allele frequencies of the −2578C/A and +936C/T polymorphism in DNA samples of 431 patients with NHL using restriction fragment length polymorphism typing analysis.

Results

The −2578A allele was significantly associated with less frequent clinical staging III, IV and bone marrow involvement (The odds ratio (OR) 0.59; 95% confidence interval (CI) 0.43–0.82; and OR 0.66; 95% CI 0.48–0.91, respectively). The CA and CA + AA genotype of the −2578C/A were significantly associated with less frequent bone marrow involvement than CC genotypes (OR 0.57; 95% CI 0.38–0.86; and OR 0.57; 95% CI 0.39–0.85, respectively). The TT genotype of the +936C/T polymorphism was significantly associated with less frequent T cell histological type, clinical staging III, IV and bone marrow involvement (OR 0.25; 95% CI 0.07–0.89; OR 0.37; 95% CI 0.15–0.89; and OR 0.31; 95% CI 0.10–0.96, respectively). The +936 T allele was marginally associated with less frequent bone marrow involvement and with Clinical staging III, IV (OR 0.71; 95% CI 0.49–1.01; and OR 0.70; 95% CI 0.49–1.00, respectively). None of the evaluated genotypes of −2578C/A was significantly associated with the gender, age, tumor size, B symptoms and immunohistological subtype. No significant associations between the genotype of +936C/T and the clinicopathologic variables, gender, age, tumor size and B symptoms were ascertained. Both of the −2578C/A and +936C/T polymorphisms were not related to the patients’ overall survival.

Conclusion

We present the first data on VEGF gene polymorphisms in NHL. Our findings support the hypothesis that the −2578 CA and CA + AA and +936 TT VEGF genotypes and −2578A and +936T alleles are associated with decreased risk for invasion. But the investigated VEGF gene polymorphisms were not associated with prognosis in patients with NHL.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2

References

  1. Dong X, Han ZC, Yang R (2007) Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol 62:105–118

  2. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4–25

  3. Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9:669–676

  4. Ganjoo KN, Moore AM, Orazi A, Sen JA, Johnson CS, An CS (2007) The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. J Cancer Res Clin Oncol 134:381–387

  5. Hazar B, Paydas S, Zorludemir S, Sahin B, Tuncer I (2003) Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin’s lymphoma. Leuk Lymphoma 44:2089–2093

  6. Hefler LA, Mustea A, Könsgen D, Concin N, Tanner B, Strick R, Heinze G, Grimm C, Schuster E, Tempfer C, Reinthaller A, Zeillinger R (2007) Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res 13:898–901

  7. Ho CL, Sheu LF, Li CY (2002) Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma. Appl Immunohistochem Mol Morphol 10:316–321

  8. Ho CL, Sheu LF, Li CY (2003) Immunohistochemical expression of angiogenic cytokines and their receptors in reactive benign lymph nodes and non-Hodgkin lymphoma. Ann Diagn Pathol 7:1–8

  9. Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM (2002) Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumor development in cutaneous malignant melanoma. Genes Immun 3:229–232

  10. Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, Henriksson R, Chen B, Pamula J, Pekala W, Zientek H, Rogozinska-Szczepka J, Utracka-Hutka B, Hallmans G, Försti A (2005) Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res 11:3647–3653

  11. Jorgensen JM, Sorensen FB, Bendix K, Nielsen JL, Olsen ML, Funder AM, d’Amore F (2007) Angiogenesis in non-Hodgkin’s lymphoma: clinico-pathological correlations and prognostic significance in specific subtypes. Leuk Lymphoma 48:584–595

  12. Kataoka N, Cai Q, Wen W, Shu XO, Jin F, Gao YT, Zheng W (2006) Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol Biomarkers Prev 15:1148–1152

  13. Kawai Y, Sakano S, Korenaga Y, Eguchi S, Naito K (2007) Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. Eur Urol 52:1147–1155

  14. Kim EJ, Jeong P, Quan C, Kim J, Bae SC, Yoon SJ, Kang JW, Lee SC, Jun Wee J, Kim WJ (2005) Genotypes of TNF-a, VEGF, hOGG1, GSTM1, and GSTT1: useful determinants for clinical outcome of bladder cancer. Urology 65:70–75

  15. Koster A, van Krieken JH, Mackenzie MA, Schraders M, Borm GF, van der Laak JA, Leenders W, Hebeda K, Raemaekers JM (2005) Increased vascularization predicts favorable outcome in follicular lymphoma. Clin Cancer Res 11:154–161

  16. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46:293–298

  17. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC, Paulweber B, Haas J, Samonigg H (2003) A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 106:468–471

  18. Lee SJ, Lee SY, Jeon HS, Park SH, Jang JS, Lee GY, Son JW, Kim CH, Lee WK, Kam S, Park RW, Park TI, Kang YM, Kim IS, Jung TH, Park JY (2005) Vascular endothelial growth factor gene polymorphisms and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 14:571–575

  19. Marcus R (2005) Use of 90Y-ibritumomab tiuxetan in non-Hodgkin’s lymphoma. Semin Oncol 32:36–43

  20. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell WM (2002) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62:3369–3372

  21. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215

  22. Polterauer S, Grimm C, Mustea A, Concin N, Tanner B, Thiel F, Heinze G, Reinthaller A, Zeillinger R, Hefler LA (2007) Vascular endothelial growth factor gene polymorphisms in ovarian cancer. Gynecol Oncol 105:385–389

  23. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E (2000) A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 37:443–448

  24. Salven P, Orpana A, Teerenhovi L, Joensuu H (2000) Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. Blood 96:3712–3718

  25. Schneider BP, Radovich M, Sledge GW, Robarge JD, Li L, Storniolo AM, Lemler S, Nguyen AT, Hancock BA, Stout M, Skaar T, Flockhart DA (2007) Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res Treat 113:197–198

  26. Stevens A, Soden J, Brenchley PE, Ralph S, Ray DW (2003) Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res 68:812–816

  27. Tzanakis N, Gazouli M, Rallis G, Giannopoulos G, Papaconstantinou I, Theodoropoulos G, Pikoulis E, Tsigris C, Karakitsos P, Peros G, Nikiteas N (2006) Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol 94:624–630

  28. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE (2000) Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 12:1232–1235

  29. Yapijakis C, Vairaktaris E, Vassiliou S, Vylliotis A, Nkenke E, Nixon AM, Derka S, Spyridonidou S, Vorris E, Neukam F, Patsouris E (2007) The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer. J Cancer Res Clin Oncol 133:787–791

Download references

Acknowledgments

This study was supported in part by the institution of higher learning strong and special subjects item Foundation, Hebei province, China.

Conflict of Interest Statement

We have not conflict of interest statement with anyone and institutes.

Author information

Correspondence to Shi-Jie Wang.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Diao, L., Yu, X., Gao, Y. et al. Association of VEGF genetic polymorphisms with the clinical characteristics of non-Hodgkin’s lymphoma. J Cancer Res Clin Oncol 135, 1473–1481 (2009). https://doi.org/10.1007/s00432-009-0650-0

Download citation

Keywords

  • VEGF
  • Genotype
  • Alleles
  • Non-Hodgkin’s lymphoma
  • Polymorphism